Significant contract signed to manufacture lateral flow device components
Abingdon Health PLC (AIM:ABDX) Significant contract to manufacture LFD components
Avacta Group PLC (AIM:AVCT) AffyXell expands partnership with GenScript ProBio
AffyXell, Avacta’s joint venture with Daewoong Pharmaceutical, expands its manufacturing partnership with GenScript ProBio for cell therapies
Abingdon Health PLC (AIM:ABDX) Strategic collaboration with Bimelix Ab
Focused on the on development and commercialisation of Lyme disease lateral flow self-test
Avacta Group PLC (AIM:AVCT) London Therapeutics headquarters established
Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus
Avacta Group PLC (AIM:AVCT) AffyXell milestone and increased equity stake
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a
Avacta Group PLC (AIM:AVCT) Poster presented at the AACR available to download
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms.
Avacta Group PLC (AIM:AVCT) AffyXell partners with Biocytogen and KNTSC
AffyXell partners with Biocytogen and the Korea Non-clinical Technology Support Center
Abingdon Health PLC (AIM:ABDX) Completion of Technical Transfer & initial orders
Completion of Technical Transfer to full-scale manufacture and initial orders for Vatic KnowNowTM test
Deepverge PLC (AIM:DVRG) MoU with Abingdon Health for lateral flow tests
DeepVerge and Abingdon Health plc sign MoU for Commercial Agreement for Lateral Flow Tests in Modern Water Household Devices
Avacta Group PLC (AVCT.L) Dose escalation in the phase I trial of AVA6000
Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin
Avacta Group PLC (AVCT.L) Second pre|CISION Pro-drug Candidate Selected
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces that the next pre|CISIONTM
